|Bid||56.00 x 2600|
|Ask||59.75 x 2000|
|Day's Range||56.10 - 58.60|
|52 Week Range||38.14 - 66.60|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Aerie's facility in Durham is the company's largest in the U.S., with more than 45,000 square feet, upward of 50 employees, and a unique mix of laboratory and office space – at a ratio of about 60 percent to 40 percent. For Aerie, "regardless of size, Durham remains an important center of gravity for the company, with our heritage in the work of Dr. David Epstein at Duke, the drug discovery and pre-clinical science that led to our breakthrough first product in glaucoma and our large kinase library, and the ongoing development work that is filling our product pipeline," says Heitmann.
Short interest is moderately high for AERI with between 10 and 15% of shares outstanding currently on loan. The $201 million in inflows that ETFs holding AERI received over the last one-month is a decline from earlier in the period and among the weakest of the past year.
The Irvine, California-based company said it had a loss of $1.60 per share. Losses, adjusted for non-recurring costs, were $1.38 per share. The results missed Wall Street expectations. The average estimate ...
Aerie Pharmaceuticals (AERI) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
Aerie (AERI) looks poised for a beat when it reports Q4 results (due on Feb 28) on the back of lead drug Rhopressa's approval.
Short interest is moderately high for AERI with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on February 6. Over the last one-month, outflows of investor capital in ETFs holding AERI totaled $396 million.
Despite the red-hot stock market, there remains some good buys. Here are several names to consider, one of them being Chinese eCommerce giant Alibaba.
Short interest is moderately high for AERI with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding AERI totaled $3.57 billion.
For Aerie Pharmaceuticals (AERI) – a Duke University spinout that is in the process of building out its research and development team locally – Christmas did indeed come early . The company also said it has plans to hire a sprawling field sales force. "We are proud of the work we have done, which ultimately culminated in the early approval of Rhopressa," a company representative said last week.
This week's pharma sector highlights include the FDA approval of Aerie's (AERI) Rhopressa as well as the label expansion of Pfizer's Bosulif and Bristol-Myers's Opdivo.
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Aerie Pharmaceuticals Inc (NASDAQ:AERI) with a market-capitalization of $2.14B, rarely draw their attention and few analysts coverRead More...
A Relative Strength Rating upgrade for Aerie Pharmaceuticals shows improving technical performance.
Aerie (AERI) got a significant boost with the FDA approving its lead drug Rhopressa for the lowering of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, ahead of schedule.
Glaucoma affects about 2.7 million people in the United States and is the second leading cause of blindness in the world. Rhopressa helps lower the pressure due to a build up of fluid in the eye by targeting the trabecular meshwork, the main drain through which fluid flows out of the eye. Aerie's marketing application for Rhopressa in 2016 was delayed due to issues with the Florida-based facility where it was being manufactured.
Aerie Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration (FDA) approved its eyedrop, Rhopressa, as a treatment for glaucoma, two months ahead of the expected date. The company is planning to launch the drug by the middle of second quarter (Apr-Jun)in 2018 and around the same time aims to seek FDA approval for its second glaucoma eyedrop, Roclatan. "We have been preparing for commercialization for well over a year," Chief Executive Vicente Anido Jr said in a statement, adding that Aerie would hire 100 sales representatives early next year.
Aerie Pharmaceuticals Inc. announced Monday afternoon that the Food and Drug Administration has approved a medication developed to relieve pressure in patients suffering from glaucoma or ocular hypertension. ...
Aerie Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration approved its treatment for glaucoma, Rhopressa. The approval was given two months ahead of the expected date, the company ...
Aerie (AERI) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Aerie Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 85.
Aerie Pharmaceuticals (AERI) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Categories: Yahoo FinanceGet free summary analysis Company Profile Aerie Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The company’s product candidates are Rhopressa and Roclatan. Aerie Pharmaceuticals was founded by David L. Epstein, Casey ... Read more (Read more...)
Short interest is moderately high for AERI with between 10 and 15% of shares outstanding currently on loan. The net inflows of $2.30 billion over the last one-month into ETFs that hold AERI are not among the highest of the last year and have been slowing.